Cancer, Immunotherapy
Conditions
Keywords
Immunotherapy, Cancer, Diversity In Immunotherapy Clinical Trials
Brief summary
It has been observed before that participation in medical trials has been in favor of specific demographic groups. But research pointing out which trial attributes impact participation positively or negatively is sparse. This study invites various participants to collect more data on their immunotherapy clinical experiences. The goal is to know which factors always limit how patients participate or complete the medical study they are first interested in. The data obtained in the trial will be assessed through a variety of demographic lenses to discover patterns that might improve the experience of immunotherapy patients in the future.
Interventions
None listed
Sponsors
Power Life Sciences Inc.
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient has self-identified as planning to participate in an interventional clinical trial using immunotherapy * Patient has been diagnosed with a type of cancer * Patient is a minimum of 18 years or older
Exclusion criteria
* Patient has an ECOG score of 4 or higher * Patient is not able to provide consistent digital reporting as per study requirements * Patient does not complete Informed Consent Form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients who decide to enroll in an immunotherapy clinical trial | 3 months |
| Rate of patients who remain in immunotherapy clinical trial to trial completion | 12 months |
Contacts
Primary ContactMichael B Gill
Outcome results
None listed